Clinical usefulness of cell-free and concentrated ascites reinfusion therapy (CART) in combination with chemotherapy for malignant ascites: a post-marketing surveillance study
Author:
Publisher
Springer Science and Business Media LLC
Subject
Oncology,Hematology,General Medicine,Surgery
Link
https://link.springer.com/content/pdf/10.1007/s10147-021-01883-2.pdf
Reference22 articles.
1. Zaak D, Paquet KJ, Kuhn R (2001) Prospective study comparing human albumin vs. reinfusion of ultrafiltrate-ascitic fluid after total paracentesis in cirrhotic patients with tense ascites. Z Gastroenterol 39:5–10. https://doi.org/10.1055/s-2001-10707
2. Cohen M, Petignat P (2014) The bright side of ascites in ovarian cancer. Cell Cycle 13:2319. https://doi.org/10.4161/cc.29951
3. Davis HA, Blalock JF (1939) Autologous and homologous transfusion of human ascitic fluid. J Clin Invest 18:219–224. https://doi.org/10.1172/JCI101037
4. Ito T, Hanafusa N, Iwase S et al (2015) Effects of cell-free and concentrated ascites reinfusion therapy (CART) on symptom relief of malignancy-related ascites. Int J Clin Oncol 20:623–628. https://doi.org/10.1007/s10147-014-0750-y
5. Maeda O, Ando T, Ishiguro K et al (2014) Safety of repeated cell-free and concentrated ascites reinfusion therapy for malignant ascites from gastrointestinal cancer. Mol Clin Oncol 2:1103–1106. https://doi.org/10.3892/mco.2014.335
Cited by 7 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Feasibility and efficacy of cell-free and concentrate ascites reinfusion therapy (CART) for advanced pancreatic cancer patients with massive malignant ascites;Pancreatology;2024-09
2. Reappraisal of a Renovated Cell-free and Concentrated Ascites Reinfusion Therapy for Malignant Ascites;Anticancer Research;2024-02
3. Advances in the treatment of malignant ascites in China;Supportive Care in Cancer;2024-01-11
4. Reappraisal of a renovated cell-free and concentrated ascites reinfusion therapy (KM-CART) for malignant ascites;2023-09-12
5. Occurrence of fever in cell-free and concentrated ascites reinfusion therapy is not related to the primary disease or nature of ascites;Journal of Artificial Organs;2023-05-13
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3